- Home
- IONS vs NXST Comparison
IONS vs NXST Comparison
Compare IONS & NXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- NXST
- Stock Information
- Founded
- IONS 1989
- NXST 1996
- Country
- IONS United States
- NXST United States
- Employees
- IONS N/A
- NXST N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- NXST Broadcasting
- Sector
- IONS Health Care
- NXST Industrials
- Exchange
- IONS Nasdaq
- NXST Nasdaq
- Market Cap
- IONS 4.6B
- NXST 5.0B
- IPO Year
- IONS 1991
- NXST 2003
- Fundamental
- Price
- IONS $28.40
- NXST $147.50
- Analyst Decision
- IONS Buy
- NXST Strong Buy
- Analyst Count
- IONS 18
- NXST 7
- Target Price
- IONS $57.00
- NXST $208.43
- AVG Volume (30 Days)
- IONS 2.0M
- NXST 641.8K
- Earning Date
- IONS 04-30-2025
- NXST 05-08-2025
- Dividend Yield
- IONS N/A
- NXST 4.88%
- EPS Growth
- IONS N/A
- NXST 122.09
- EPS
- IONS N/A
- NXST 21.41
- Revenue
- IONS $705,138,000.00
- NXST $5,407,000,000.00
- Revenue This Year
- IONS N/A
- NXST N/A
- Revenue Next Year
- IONS $25.80
- NXST $9.73
- P/E Ratio
- IONS N/A
- NXST $6.89
- Revenue Growth
- IONS N/A
- NXST 9.61
- 52 Week Low
- IONS $23.95
- NXST $143.32
- 52 Week High
- IONS $52.34
- NXST $191.86
- Technical
- Relative Strength Index (RSI)
- IONS 44.54
- NXST 35.26
- Support Level
- IONS $27.57
- NXST $145.90
- Resistance Level
- IONS $29.04
- NXST $156.22
- Average True Range (ATR)
- IONS 1.79
- NXST 7.95
- MACD
- IONS 0.12
- NXST -2.37
- Stochastic Oscillator
- IONS 68.15
- NXST 10.82
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About NXST Nexstar Media Group Inc.
Nexstar Media Group Inc is the largest television station owner-operator in the United States with over 200 stations in 116 markets. Of its 200 stations, 155 are affiliated with the four national broadcast networks: CBS, Fox, NBC, and ABC. The 2019 merger with Tribune made Nexstar the top broadcast affiliate for both Fox and CBS as well as the number-two partner for NBC and number three for ABC. The firm has stations in 12 of the top 20 television markets and reaches 68% of us TV households. Nexstar also owns NewsNation (formerly WGN), a nationwide pay-television network, 75% of The CW, and a 31% stake in Food Network and Cooking Channel.